Skip to content
OpenCapital
Get started

SION SION Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss

Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
——

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.86B—

Returns & leverage

See full
Return on equity-26.7%—
Debt / equity0×0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
SION (SION) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $226.69M in Q1 2026.
How has SION's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss changed year-over-year?
SION's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss decreased by 16.6% year-over-year, from $271.69M to $226.69M.